Valeant Commences Exchange Offer For Allergan

From Valeant Pharmaceuticals

Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it has commenced an exchange offer for the common stock of Allergan, Inc. ("Allergan") (NYSE: AGN), taking its May 30th proposal directly to Allergan stockholders. Under the terms of the offer, Allergan stockholders would be able to elect to exchange...

Read full article

Friday, July 11, 2014

Show last days of articles

The 25th Neuronal Plasticity Prize of the Fondation Ipsen is...

From NeurologyWire

The 25th annual Neuronal Plasticity Prize of the Fondation Ipsen has been awarded to three researchers for their pioneer works in the domain of Neurop...Full story

Neurelis Regains Rights to Intranasal Diazepam Program

From NeurologyWire

Neurelis, Inc. announced an agreement with Biotie Therapies Corp. to end the option held by Biotie to purchase Neurelis, clearing the way for Neurelis...Full story

Thursday, July 10, 2014

Human Stem Cells Effectively Treat MS in Mice Models

From NeurologyWire

Scientists in the University of Connecticuts Technology Incubation Program have identified a novel approach to treating multiple sclerosis (MS) using ...Full story

Wednesday, July 09, 2014

Actavis Confirms Generic Ampyra Patent Challenge

From NeurologyWire

Actavis confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to ma...Full story

Research Tool Pinpoints Potential Therapies for MS

From NeurologyWire

Using a novel screening platform to rapidly evaluate the cellular effects of 1,000 chemical compounds, a team led by UC San Francisco scientists has i...Full story

Tuesday, July 08, 2014

Little benefit from corticosteroids for spinal stenosis

From NeurologyWire

The addition of a corticosteroid to epidural injections of an anesthetic does not enhance pain reduction in patients with lumbar spinal stenosis, a co...Full story

Monday, July 07, 2014

Lemtrada Approved in Scotland

From NeurologyWire

The Scottish Medicines Consortium (SMC) today published its advice that Lemtrada (alemtuzumab) has been accepted for use within NHS Scotland for the t...Full story

MRIs detect early Parkinson's

From NeurologyWire

Oxford University researchers say they have developed a simple and quick MRI technique that offers promise for early diagnosis of Parkinson's disease....Full story

Wednesday, July 02, 2014

Tardive dyskinesia treatments get $20 million in funding

From NeurologyWire

Synchroneuron Inc., a biopharmaceutical company engaged in developing new therapies to treat tardive dyskinesia (TD) and other neuropsychiatric disord...Full story

Tuesday, July 01, 2014

Actavis Plans Generic Version of Acordas MS Drug Ampyra

From NeurologyWire

Acorda Therapeutics announced receiving a notice letter from pharmaceutical company Actavis Plc indicating their plans to commercialize a generic vers...Full story

Qudexy XR Now Available for Epilepsy

From NeurologyWire

Upsher-Smith announced the launch of Qudexy XR (topiramate) extended-release capsules. Qudexy XR was approved in March 2014 as initial monotherapy in ...Full story

Research links Alzheimer's to brain hyperactivity

From NeurologyWire

Patients with Alzheimer's disease run a high risk of seizures. While the amyloid-beta protein involved in the development and progression of Alzheimer...Full story

Monday, June 30, 2014

Epilepsy Treatment Shown to Have Retained Seizure Control an...

From NeurologyWire

The results of an interim analysis of the non-interventional EPOS (Eslicarbazepine acetate in Partial-Onset Seizure) study presented this week at the ...Full story

ALS Protein Clearance is Key to Neuron Survival

From NeurologyWire

In work supported by The ALS Association, researchers have shown that increasing the clearance of misfolded protein from neurons improves their surviv...Full story

Stroke drug desmoteplase fails Phase III trial

From NeurologyWire

Lundbeck's acute ischaemic stroke drug desmoteplase has failed its Phase III trial. The first of two phase III clinical studies (DIAS-3) in patients w...Full story